Osteoporosis International

, Volume 19, Issue 9, pp 1277–1282 | Cite as

Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study

  • H. A. FinkEmail author
  • M. A. Kuskowski
  • B. C. Taylor
  • J. T. Schousboe
  • E. S. Orwoll
  • K. E. Ensrud
  • for the Osteoporotic Fractures in Men (MrOS) Study Group
Original Article



Among community-dwelling older men, compared to those without Parkinson’s disease (PD), over approximately 5 years, those with baseline PD had a significantly greater rate of annualized total hip bone loss (−1.1% vs. 0.4%), proportion of incident non-spine fractures (14.9% vs. 7.2%) and mortality (34.8% vs. 9.5%).


The objective of this study was to examine the association of Parkinson’s disease (PD) with bone loss and fractures in older men.


This prospective cohort study analyzed data from 5,937 community dwelling men aged ≥65 years at six clinical centers of the Osteoporotic Fractures in Men (MrOS) Study. At baseline and visit two (mean interval 4.6 +/−0.4 SD years), community-diagnosed PD was ascertained by self-report and hip bone mineral density (BMD) was measured using dual energy x-ray absorptiometry (DXA). Incident fractures were self-reported. Fractures and deaths were centrally adjudicated.


At baseline, 46 (0.8%) men had PD. Age-adjusted mean annualized total hip bone loss was greater in men with vs. those without PD (−1.08% vs. −0.36%, p < 0.001). 15.2% of men with PD and 7.2% of men without PD experienced an incident non-spine fracture (age-adjusted HR 2.4, 95%CI 1.1–5.0). 34.8% of men with PD and 9.5% of men without PD died during follow-up (age-adjusted HR 3.5, 95%CI 2.2–5.5). Associations of PD with bone loss, fractures and mortality were modestly altered by additional individual adjustment for possible confounders.


In community-dwelling older men, PD was associated with increased bone loss, fractures and mortality. In addition to implementing fall prevention measures, clinicians should consider osteoporosis screening in older men with PD.


Bone density Fractures Mortality Osteoporosis Parkinson’s disease 


Potential financial conflicts of interest

Dr. Schousboe receives research grant support from Hologic, Inc. Dr. Ensrud receives research grant support from Bionovo. Dr. Orwoll receives research, consulting or speaking support from Aventis, Pfizer, Eli Lilly & Co., Novartis, Merck & Co., Procter & Gamble, GlaxoSmithKline, Zelos Therapeutics Inc., Imaging Therapeutics Ind., and Solvay Pharmaceuticals. All other authors have no conflicts of interest.

Author contributions

Conception and design: H.A. Fink, M.A. Kuskowski

Acquisition of participants and/or data: E.S. Orwoll, K.E. Ensrud

Analysis and interpretation of the data: H.A. Fink, M.A. Kuskowski, B.C. Taylor, J.T. Schousboe, K.E. Ensrud

Drafting of the article: H.A. Fink

Critical revision of the article for important intellectual content: H.A. Fink, M.A. Kuskowski, B.C. Taylor, J.T. Schousboe, E.S. Orwoll, K.E. Ensrud

Final approval of the article: H.A. Fink, M.A. Kuskowski, B.C. Taylor, J.T. Schousboe, E.S. Orwoll, K.E. Ensrud

Sponsor’s role

The funding agencies played no role in the design, analysis and preparation of this manuscript.


  1. 1.
    Sato Y, Kikuyama M, Oizumi K (1997) High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 49:1273–1278PubMedGoogle Scholar
  2. 2.
    Taggart H, Crawford V (1995) Reduced bone density of the hip in elderly patients with Parkinson’s disease. Age Ageing 24:326–328PubMedCrossRefGoogle Scholar
  3. 3.
    Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH (1994) Bone mineral density in patients with Parkinson’s disease measured by dual photon absorptiometry. Nucl Med Commun 15:173–177PubMedCrossRefGoogle Scholar
  4. 4.
    Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE (2005) Association between Parkinson’s disease and low bone density and falls in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 53:1559–1564PubMedCrossRefGoogle Scholar
  5. 5.
    Sato Y, Manabe S, Kuno H, Oizumi K (1999) Amelioration of osteopenia and hypovitaminosis D by 1alpha- hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:64–68PubMedCrossRefGoogle Scholar
  6. 6.
    Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K (2002) Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency. Bone 31:114–118PubMedCrossRefGoogle Scholar
  7. 7.
    Johnell O, Melton LJ III, Atkinson EJ, O’Fallon WM, Kurland LT (1992) Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38PubMedCrossRefGoogle Scholar
  8. 8.
    Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O’Brien LA, Hoffman S, Kaplan F (1991) Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med 324:1326–1331PubMedCrossRefGoogle Scholar
  9. 9.
    Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 34:21–24PubMedCrossRefGoogle Scholar
  10. 10.
    Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ, Ensrud KE (2004) Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 52:1479–1486PubMedCrossRefGoogle Scholar
  11. 11.
    Blank JB, Cawthon PM, Carrion-Petersen ML, Harper L, Johnson JP, Mitson E, Delay RR (2005) Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials 26:557–568PubMedCrossRefGoogle Scholar
  12. 12.
    Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, Lewis C, Cawthon PM, Marcus R, Marshall LM, McGowan J, Phipps K, Sherman S, Stefanick ML, Stone K (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569–585PubMedCrossRefGoogle Scholar
  13. 13.
    Washburn RA, Smith KW, Jette AM, Janney CA (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46:153–162PubMedCrossRefGoogle Scholar
  14. 14.
    Drugs for Parkinson’s disease (2007) Treat Guidel Med Lett 5:89–94Google Scholar
  15. 15.
    Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233PubMedCrossRefGoogle Scholar
  16. 16.
    Hamilton A, Balnave R, Adams R (1994) Grip strength testing reliability. J Hand Ther 7:163–170PubMedGoogle Scholar
  17. 17.
    Nevitt MC, Cummings SR, Kidd S, Black D (1989) Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA 261:2663–2668Google Scholar
  18. 18.
    Bassey EJ, Short AH (1990) A new method for measuring power output in a single leg extension: feasibility, reliability and validity. Eur J Appl Physiol Occup Physiol 60:385–390PubMedCrossRefGoogle Scholar
  19. 19.
    Eng ML, Lyons KE, Pahwa R (2006) Prevalence of bone mineral density screening in Parkinson’s disease clinic outpatients. Mov Disord 21:2265–2266PubMedCrossRefGoogle Scholar
  20. 20.
    Sato Y, Honda Y, Iwamoto J (2007) Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 68:911–915PubMedCrossRefGoogle Scholar
  21. 21.
    Sato Y, Iwamoto J, Kanoko T, Satoh K (2006) Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord 21:924–929PubMedCrossRefGoogle Scholar
  22. 22.
    Bakhireva LN, Barrett-Connor E, Kritz-Silverstein D, Morton DJ (2004) Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med 26:436–442PubMedCrossRefGoogle Scholar
  23. 23.
    Szulc P, Delmas PD (2007) Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition. The prospective MINOS study. Osteoporos Int 18:495–503PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

Authors and Affiliations

  • H. A. Fink
    • 1
    • 2
    • 3
    • 4
    • 8
    Email author
  • M. A. Kuskowski
    • 1
  • B. C. Taylor
    • 2
    • 4
  • J. T. Schousboe
    • 5
    • 6
  • E. S. Orwoll
    • 7
  • K. E. Ensrud
    • 2
    • 3
    • 4
  • for the Osteoporotic Fractures in Men (MrOS) Study Group
  1. 1.Geriatric Research Education and Clinical CenterVA Medical CenterMinneapolisUSA
  2. 2.Center for Chronic Disease Outcomes ResearchVA Medical CenterMinneapolisUSA
  3. 3.Department of MedicineUniversity of MinnesotaMinneapolisUSA
  4. 4.Division of Epidemiology, School of Public HealthUniversity of MinnesotaMinneapolisUSA
  5. 5.Division of Health Services Research and Policy, School of Public HealthUniversity of MinnesotaMinneapolisUSA
  6. 6.Division of RheumatologyPark Nicollet Health ServicesMinneapolisUSA
  7. 7.Bone and Mineral UnitOregon Health & Science UniversityPortlandUSA
  8. 8.VA Medical CenterMinneapolisUSA

Personalised recommendations